{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:42:48Z","timestamp":1793292168405,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.82472012"],"award-info":[{"award-number":["No.82472012"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fujian Provincial Clinical Key Specialty Construction Project","award":["No.2023SZDZK-HYXK"],"award-info":[{"award-number":["No.2023SZDZK-HYXK"]}]},{"name":"Joint Funds for the Innovation of Science and Technology, Fujian Province","award":["No.2021Y9134"],"award-info":[{"award-number":["No.2021Y9134"]}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["No.2022J01683"],"award-info":[{"award-number":["No.2022J01683"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["No.2023J01584"],"award-info":[{"award-number":["No.2023J01584"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00259-025-07444-3","type":"journal-article","created":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T07:23:04Z","timestamp":1752304984000},"page":"362-373","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The value of serial [\u2076\u2078Ga]Ga-FAPI-04 PET\/CT in predicting pathological response and evaluating therapeutic efficacy to neoadjuvant chemotherapy in breast cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Shan","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuqi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zezhong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youzhi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dairong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibing","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,12]]},"reference":[{"key":"7444_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39:1485\u2013505. https:\/\/doi.org\/10.1200\/JCO.20.03399.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"7444_CR2","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.breast.2022.01.006","volume":"62","author":"N Harbeck","year":"2022","unstructured":"Harbeck N. Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer. Breast. 2022;62(Suppl 1):S12\u20136. https:\/\/doi.org\/10.1016\/j.breast.2022.01.006.","journal-title":"Breast"},{"key":"7444_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8.","journal-title":"Lancet"},{"key":"7444_CR4","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.22.02571","volume":"41","author":"B Fisher","year":"2023","unstructured":"Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 2023;41:1795\u2013808. https:\/\/doi.org\/10.1200\/JCO.22.02571.","journal-title":"J Clin Oncol"},{"key":"7444_CR5","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee S-J, Ohtani S, Im Y-H, Lee E-S, Yokota I, et al. Adjuvant capecitabine for breast Cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147\u201359. https:\/\/doi.org\/10.1056\/NEJMoa1612645.","journal-title":"N Engl J Med"},{"key":"7444_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-Positive breast Cancer. N Engl J Med. 2019;380:617\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1814017.","journal-title":"N Engl J Med"},{"key":"7444_CR7","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/jso.25663","volume":"120","author":"SF Sener","year":"2019","unstructured":"Sener SF, Sargent RE, Lee C, Manchandia T, Le-Tran V, Olimpiadi Y, et al. MRI does not predict pathologic complete response after neoadjuvant chemotherapy for breast cancer. J Surg Oncol. 2019;120:903\u201310. https:\/\/doi.org\/10.1002\/jso.25663.","journal-title":"J Surg Oncol"},{"key":"7444_CR8","doi-asserted-by":"publisher","first-page":"7421","DOI":"10.1245\/s10434-021-10117-8","volume":"28","author":"FK Palshof","year":"2021","unstructured":"Palshof FK, Lanng C, Kroman N, Benian C, Vejborg I, Bak A, et al. Prediction of pathologic complete response in breast Cancer patients comparing magnetic resonance imaging with ultrasound in neoadjuvant setting. Ann Surg Oncol. 2021;28:7421\u20139. https:\/\/doi.org\/10.1245\/s10434-021-10117-8.","journal-title":"Ann Surg Oncol"},{"key":"7444_CR9","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1200\/JCO.2010.31.1258","volume":"29","author":"CE Loo","year":"2011","unstructured":"Loo CE, Straver ME, Rodenhuis S, Muller SH, Wesseling J, Vrancken Peeters MJ, et al. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol. 2011;29:660\u20136. https:\/\/doi.org\/10.1200\/JCO.2010.31.1258.","journal-title":"J Clin Oncol"},{"key":"7444_CR10","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1007\/s00259-024-06815-6","volume":"51","author":"C Oliveira","year":"2024","unstructured":"Oliveira C, Oliveira F, Constantino C, Alves C, Brito MJ, Cardoso F, et al. Baseline [(18)F]FDG PET\/CT and MRI first-order breast tumor features do not improve pathological complete response prediction to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2024;51:3709\u201318. https:\/\/doi.org\/10.1007\/s00259-024-06815-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7444_CR11","unstructured":"National Comprehensive Cancer Network. (2025) NCCN Guidelines in Oncology (NCCN Guidelines\u00ae)| Breast Cancer. Version 4.2025. April 17, 2025. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"key":"7444_CR12","doi-asserted-by":"publisher","first-page":"10832","DOI":"10.1073\/pnas.89.22.10832","volume":"89","author":"WJ Rettig","year":"1992","unstructured":"Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Jaffe EA, Old LJ. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci U S A. 1992;89:10832\u20136. https:\/\/doi.org\/10.1073\/pnas.89.22.10832.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7444_CR13","doi-asserted-by":"publisher","first-page":"7235","DOI":"10.1073\/pnas.87.18.7235","volume":"87","author":"P Garin-Chesa","year":"1990","unstructured":"Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A. 1990;87:7235\u20139. https:\/\/doi.org\/10.1073\/pnas.87.18.7235.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7444_CR14","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","volume":"59","author":"T Lindner","year":"2018","unstructured":"Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of Quinoline-Based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415\u201322. https:\/\/doi.org\/10.2967\/jnumed.118.210443.","journal-title":"J Nucl Med"},{"key":"7444_CR15","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.118.215913","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, et al. (68)Ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-Containing FAP-Targeting agents in patients with various cancers. J Nucl Med. 2019;60:386\u201392. https:\/\/doi.org\/10.2967\/jnumed.118.215913.","journal-title":"J Nucl Med"},{"key":"7444_CR16","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. (68)Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of Cancer. J Nucl Med. 2019;60:801\u20135. https:\/\/doi.org\/10.2967\/jnumed.119.227967.","journal-title":"J Nucl Med"},{"key":"7444_CR17","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","volume":"47","author":"H Chen","year":"2020","unstructured":"Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, et al. Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F] FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020;47:1820\u201332. https:\/\/doi.org\/10.1007\/s00259-020-04769-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7444_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2967\/jnumed.120.258467","volume":"63","author":"C Qin","year":"2022","unstructured":"Qin C, Shao F, Gai Y, Liu Q, Ruan W, Liu F, et al. (68)Ga-DOTA-FAPI-04 PET\/MR in the evaluation of gastric carcinomas: comparison with (18)F-FDG PET\/CT. J Nucl Med. 2022;63:81\u20138. https:\/\/doi.org\/10.2967\/jnumed.120.258467.","journal-title":"J Nucl Med"},{"key":"7444_CR19","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1097\/RLU.0000000000004523","volume":"48","author":"S Zheng","year":"2023","unstructured":"Zheng S, Lin J, Zhu Y, Chen Y, Zhang J, Chen X, et al. 68Ga-FAPI versus 18F-FDG PET\/CT in evaluating newly diagnosed breast Cancer patients: A Head-to-Head comparative study. Clin Nucl Med. 2023;48:e104\u20139. https:\/\/doi.org\/10.1097\/RLU.0000000000004523.","journal-title":"Clin Nucl Med"},{"key":"7444_CR20","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.2967\/jnumed.123.266079","volume":"64","author":"L Chen","year":"2023","unstructured":"Chen L, Zheng S, Chen L, Xu S, Wu K, Kong L, et al. (68)Ga-Labeled fibroblast activation protein inhibitor PET\/CT for the early and late prediction of pathologic response to neoadjuvant chemotherapy in breast Cancer patients: A prospective study. J Nucl Med. 2023;64:1899\u2013905. https:\/\/doi.org\/10.2967\/jnumed.123.266079.","journal-title":"J Nucl Med"},{"key":"7444_CR21","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1200\/jco.2007.10.6823","volume":"25","author":"WF Symmans","year":"2007","unstructured":"Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast Cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:4414\u201322. https:\/\/doi.org\/10.1200\/jco.2007.10.6823.","journal-title":"J Clin Oncol"},{"key":"7444_CR22","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.2967\/jnumed.123.265712","volume":"64","author":"M Wu","year":"2023","unstructured":"Wu M, Wang Y, Yang Q, Wang X, Yang X, Xing H, et al. Comparison of baseline (68)Ga-FAPI and (18)F-FDG PET\/CT for prediction of response and clinical outcome in patients with unresectable hepatocellular carcinoma treated with PD-1 inhibitor and lenvatinib. J Nucl Med. 2023;64:1532\u20139. https:\/\/doi.org\/10.2967\/jnumed.123.265712.","journal-title":"J Nucl Med"},{"key":"7444_CR23","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/RLU.0000000000005300","volume":"49","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Guo S, Cheng C, Cao K, Jiang H, Jin G, et al. Integrated 68Ga-FAPI-04 PET\/MR in pancreatic cancer: prediction of tumor response and tumor resectability after neoadjuvant therapy. Clin Nucl Med. 2024;49:715\u201321. https:\/\/doi.org\/10.1097\/RLU.0000000000005300.","journal-title":"Clin Nucl Med"},{"key":"7444_CR24","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2967\/jnumed.122.264871","volume":"64","author":"P Backhaus","year":"2023","unstructured":"Backhaus P, Burg MC, Asmus I, Pixberg M, Buther F, Breyholz HJ, et al. Initial results of (68)Ga-FAPI-46 PET\/MRI to assess response to neoadjuvant chemotherapy in breast Cancer. J Nucl Med. 2023;64:717\u201323. https:\/\/doi.org\/10.2967\/jnumed.122.264871.","journal-title":"J Nucl Med"},{"key":"7444_CR25","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1007\/s00259-007-0459-5","volume":"34","author":"A Berriolo-Riedinger","year":"2007","unstructured":"Berriolo-Riedinger A, Touzery C, Riedinger J-M, Toubeau M, Coudert B, Arnould L, et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2007;34:1915\u201324. https:\/\/doi.org\/10.1007\/s00259-007-0459-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7444_CR26","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1007\/s00259-023-06394-y","volume":"50","author":"R-D Seban","year":"2023","unstructured":"Seban R-D, Arnaud E, Loirat D, Cabel L, Cottu P, Djerroudi L, et al. [18F]FDG PET\/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab. Eur J Nucl Med Mol Imaging. 2023;50:4024\u201335. https:\/\/doi.org\/10.1007\/s00259-023-06394-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7444_CR27","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1200\/JCO.2004.08.181","volume":"22","author":"T Hamaoka","year":"2004","unstructured":"Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22:2942\u201353. https:\/\/doi.org\/10.1200\/JCO.2004.08.181.","journal-title":"J Clin Oncol"},{"key":"7444_CR28","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/00003072-200207000-00004","volume":"27","author":"J Lemieux","year":"2002","unstructured":"Lemieux J, Guimond J, Laberge F, St-Pierre C, Cormier Y. The bone scan flare phenomenon in non-small-cell lung cancer. Clin Nucl Med. 2002;27:486\u20139. https:\/\/doi.org\/10.1097\/00003072-200207000-00004.","journal-title":"Clin Nucl Med"},{"key":"7444_CR29","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/RLU.0b013e3181a344df","volume":"34","author":"HS Chao","year":"2009","unstructured":"Chao HS, Chang CP, Chiu CH, Chu LS, Chen YM, Tsai CM. Bone scan flare phenomenon in non-small-cell lung cancer patients treated with gefitinib. Clin Nucl Med. 2009;34:346\u20139. https:\/\/doi.org\/10.1097\/RLU.0b013e3181a344df.","journal-title":"Clin Nucl Med"},{"key":"7444_CR30","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1097\/01.rlu.0000178028.13072.36","volume":"30","author":"Y Sugawara","year":"2005","unstructured":"Sugawara Y, Kajihara M, Semba T, Ochi T, Fujii T, Mochizuki T. Healing focal flare phenomenon after radiotherapy in a bone metastasis from bladder cancer. Clin Nucl Med. 2005;30:672\u20133. https:\/\/doi.org\/10.1097\/01.rlu.0000178028.13072.36.","journal-title":"Clin Nucl Med"},{"key":"7444_CR31","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.euo.2018.03.010","volume":"1","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, et al. Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway Blockade in metastatic prostate Cancer. Eur Urol Oncol. 2018;1:78\u201382. https:\/\/doi.org\/10.1016\/j.euo.2018.03.010.","journal-title":"Eur Urol Oncol"},{"key":"7444_CR32","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s00259-018-4079-z","volume":"45","author":"A Afshar-Oromieh","year":"2018","unstructured":"Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, et al. Impact of long-term androgen deprivation therapy on PSMA ligand PET\/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:2045\u201354. https:\/\/doi.org\/10.1007\/s00259-018-4079-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7444_CR33","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/RLU.0000000000001966","volume":"43","author":"KA Zukotynski","year":"2018","unstructured":"Zukotynski KA, Valliant J, Benard F, Rowe SP, Kim CK, Pomper MG, et al. Flare on serial prostate-Specific membrane Antigen-Targeted 18F-DCFPyL PET\/CT examinations in Castration-Resistant prostate cancer: first observations. Clin Nucl Med. 2018;43:213\u20136. https:\/\/doi.org\/10.1097\/RLU.0000000000001966.","journal-title":"Clin Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07444-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07444-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07444-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T05:06:12Z","timestamp":1764219972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07444-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,12]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["7444"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07444-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,12]]},"assertion":[{"value":"8 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the institutional review board of our hospital and written informed consent for publication of this report was obtained from the patient.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human participants were carried out in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any experiments with animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}